About Us

 

Founded in 2020 in Singapore, Albatroz Therapeutics focuses on developing therapeutic antibodies for extracellular matrix (ECM) remodeling disorders. ECM remodeling is broadly implicated in tissue health and disease. Fueled by our discoveries of the involvement of the Calnexin/GALA pathway in this process, we are creating new therapeutic antibodies across several disease areas, starting with cancer and arthritis.

 

founders

Frederic Bard, PhD

CEO/CSO

Guy Heathers
PhD, MBA

Vice President, Business Development

SCIENTIFIC & CLINICAL ADVISORS


 

  • We develop novel therapeutic antibodies to target extracellular matrix remodeling-associated disorders.

our science

We focus on targeting a process essential for pathogenesis of solid tumors and other disorders: remodeling of the extracellular matrix (ECM). Albatroz Therapeutics is founded on a comprehensive IP portfolio around the use and targeting of the Calnexin/GALA signaling pathway, which is critical in ECM degradation in cancer and arthritis.

 

CANCER:
SOLID TUMORS

The ECM is a physical barrier
for tumor growth and metastasis.
Matrix degradation is thus an essential
process for cancer progression and
requires reduction of the disulfide bonds that are abundant in the ECM.
Albatroz Therapeutics develops proprietary therapeutic antibodies to target Calnexin, a solid tumor surface protein essential for disulfide bonds breakage.
Our primary focus is liver cancer,
followed by lung, breast, colon and
other carcinomas.

 

 



















___________

ARTHRITIS

Calnexin also plays an essential role in the pathogenesis of arthritis, thus presenting a robust novel target.
The most prevalent forms of arthritis, osteoarthritis and rheumatoid arthritis, are characterised by remodelling of cartilage ECM by synovial fibroblasts.
Our therapeutic antibodies in the pipeline target Calnexin in synovial fibroblasts implicated in cartilage degradation.


 

 

  • We fly the distance to find new powerful treatments for patients

Contact us

 

INVESTORS

Having successfully closed its seeds funding round, Albatroz Therapeutics is currently raising Series A funding. Interested investors may contact us at info@albatroztherapeutics.com for more information.

 

OTHER ENQUIRIES

For general enquiries, please get in touch:

Your message has been sent. Thank you!
“© Albatroz Therapeutics Pte. Ltd
UEN: 202014947K | 28 WOKING ROAD #01-01 SINGAPORE 138706
Terms of Use
 
Terms of Use